QPS Global Custom-Built Regulatory Services Can Transform Clinical Trials. QPS Global Regulatory Affairs (GRA) service offerings focus on helping pharmaceutical, biotechnology, and medical device companies to develop custom-built research solutions that forge expedited regulatory pathways from discovery to global commercialization and onwards through product lifecycle support.
Whether your focus is small molecules, protein biotherapeutics, vaccines, gene therapy, or cell therapy, QPS provides a full range of bioanalytical services to support all of drug development needs from discovery, through clinical development and regulatory filing. Our dedicated, experienced team ensures that drug quantitation studies meet all timelines and regulatory requirements.
Moving quickly and safely through Phase I/IIa trials is critical to successful drug development. The QPS Phase I research facilities feature more than 550 beds across six strategically located facilities on three continents. QPS is well known for its success in first-in-human clinical trials. All Phase I sites are staffed by expert clinical pharmacology teams that routinely conduct hundreds of phase I/IIa studies annually.
At QPS, we realize that in today’s late stage drug development space you face many challenges. With our deep experience and broad global presence, QPS is in an excellent position to offer solutions to all of the above needs. With its site management & monitoring teams operating from 30 locations on three continents (Asia/Pacific, USA, and Europe), QPS has become a new strong player in Phase II/IV clinical research services.…
The QPS preclinical Neuropharmacology group covers various validated transgenic and non-transgenic in vivo and in vitro models for neurodegeneration such as Alzheimer’s Disease, Parkinson’s Disease, for rare diseases including Huntington’s Disease and ALS, for lipid storage disease and dyslipidemia, and for diseases like psychosis, anxiety, schizophrenia, or autism.
